Categories: News

LBB Specialties Expands Distribution Partnership with Clariant to Support Puerto Rico’s Life Sciences Market

NORWALK, Conn., July 9, 2025 /PRNewswire/ — LBB Specialties (LBBS), a leader in specialty chemicals and ingredient distribution in North America, is pleased to announce the expansion of its distribution partnership with Clariant, a global leader in the development and manufacturing of specialty chemical solutions. This expansion enhances LBBS’s presence in Puerto Rico’s robust Life Sciences sector, providing customers with local access to Clariant’s pharmaceutical-grade excipients, including the VitiPure product line.

- Advertisement -

Under this expanded agreement, LBB Specialties will now support the Puerto Rico market with Clariant’s full excipient portfolio, locally stocked inventory, and dedicated technical and commercial support on the island.

- Advertisement -

This collaboration strengthens LBBS’s ability to deliver high-purity, GMP-compliant excipients tailored for pharmaceutical and biopharmaceutical applications, including products designed for low endotoxin and tight microbial control.

- Advertisement -

Puerto Rico continues to be a preferred destination for companies establishing FDA-approved pharmaceutical manufacturing operations,” said Seth Burns, Senior Vice President, Life Sciences at LBB Specialties. “By expanding our partnership with Clariant, we’re reinforcing our commitment to supporting the region’s Life Sciences ecosystem with best-in-class excipients and responsive local service. This expansion builds on our shared vision of advancing formulation innovation while ensuring supply chain reliability and technical excellence.”

- Advertisement -

“This expanded partnership with LBB Specialties represents a strategic advancement in our commitment to strengthening our global footprint,” said Vaios Barlas, Head of Health Care at Clariant. “Local availability of our complete excipient portfolio directly addresses the needs of this important market. Clariant values LBBS’s established presence and technical capabilities in Puerto Rico, which complement our focus on delivering pharmaceutical-grade ingredients that meet the highest quality and regulatory standards.”

- Advertisement -

For more information about Clariant’s excipient solutions in Puerto Rico, please contact LBB Specialties today.

- Advertisement -

About LBB Specialties 
LBB Specialties is a leader in North American specialty chemicals and ingredients distribution. It is a diversified supplier serving end markets including care, food & nutrition, industrial specialties, and life sciences. www.LBBSpecialties.com

- Advertisement -

About Clariant
Clariant is a focused specialty chemical company led by the overarching purpose of “Greater chemistry – between people and planet.” By connecting customer focus, innovation, and people, the company creates solutions to foster sustainability in different industries. On 31 December 2024, Clariant totaled a staff number of 10 465 and recorded sales of CHF 4.152 billion in the fiscal year for its continuing businesses. Since January 2023, the Group conducts its business through the three Business Units Care Chemicals, Catalysts, and Adsorbents & Additives. Clariant is based in Switzerland.

- Advertisement -

Clariant Health Care is a leading high-quality solution partner for the global pharmaceutical industry, with a strong portfolio of top-performing excipients and active pharmaceutical ingredients (APIs), backed by operational excellence and years of experience in regulatory affairs. https://www.clariant.com/HealthCare

- Advertisement -

Media Contact:
Ahmed Hanafy
media@lbbspecialties.com

- Advertisement -

Logo – https://mma.prnewswire.com/media/2726987/Clariant_Logo.jpg
Logo – https://mma.prnewswire.com/media/2537440/LBB_Specialties_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/lbb-specialties-expands-distribution-partnership-with-clariant-to-support-puerto-ricos-life-sciences-market-302500574.html

- Advertisement -

Recent Posts

Vivoryon Therapeutics N.V. to Report Full Year 2025 Financial Results and Business Updates on April 23, 2026

Vivoryon Therapeutics N.V. to Report Full Year 2025 Financial Results and Business Updates on April 23,…

2 hours ago

BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026

April 15, 2026 01:00 ET  | Source: BioVersys BASEL, Switzerland, April 15, 2026 (GLOBE NEWSWIRE)…

2 hours ago

Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes

REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology…

2 hours ago

Heavy industry could grow global output while using up to 45% less energy by 2050

30-50% of costs for heavy industry come from energy consumption25-45% reduction in energy use across aluminium, aviation,…

7 hours ago

Fortune expands Asia leadership with new Editorial Directors and Brand Studio head

Seasoned executives from The Economist Group and the South China Morning Post join Fortune to…

7 hours ago

Apkudo and Qates Launch High-Volume Automated Screen Restoration System to Maximize Device Resale Value

New Powered by Apkudo technology for buff and polish combines advanced plasma treatment and precision…

7 hours ago